4-羟基-alpha,2,6-三甲基-苯丙酸 | 194857-85-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: 4-羟基-alpha,2,6-三甲基-苯丙酸
• 中文别名: 4-羟基-2,2,6-三甲基-苯丙酸
• 英文名称: 3-(4-hydroxy-2,6-dimethylbenzyl)-2-methylpropionic acid
• 英文别名: 3-(4-Hydroxy-2,6-dimethylphenyl)-2-methylpropanoic acid
• CAS: 194857-85-7
• 化学式: C₁₂H₁₆O₃
• 分子量: 208.257
• InChiKey: LPPITBJXYYCDEQ-UHFFFAOYSA-N

物化性质

• 沸点：
  385.0±37.0 °C(Predicted)
• 密度：
  1.148±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2918290000

反应信息

• 作为反应物：
  描述：

  4-羟基-alpha,2,6-三甲基-苯丙酸 在 TEA 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 27.5h， 生成 (Des-NH2-α-Me-L/D-Dmt)-Tic-OH
  参考文献：
  名称：

  Evolution of the Dmt-Tic Pharmacophore:  N-Terminal Methylated Derivatives with Extraordinary δ Opioid Antagonist Activity

  摘要：

  The delta opioid antagonist H-Dmt-Tic-OH (2',6'-dimethyl-L-tyrosyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) exhibits extraordinary delta receptor binding characteristics [K-i(delta) = 0.022 nM; K-i(u)/K-i(delta) = 150 000] and delta antagonism (pA(2) = 8.2; K-e = 5.7 nM). A change in chirality of Dmt at C alpha (1, 2, 6, 8, 10, 13) curtailed delta receptor parameters, while replacement of its alpha-amino function by a methyl group (3) led to inactivity; Tyr-Tic analogues 4 and 11 weakly interacted with delta receptors. N-Alkylation of H-Dmt-Tic-OH and H-Dmt-Tic-Ala-OH with methyl groups produced potent delta-opioid ligands with high delta receptor binding capabilities and enhanced delta antagonism: (i) N-Me-Dmt-Tic-OH 5 had high delta opioid binding (K-i(delta) = 0.2 nM), elevated delta antagonism on mouse vas deferens (MVD) (pA(2) = 8.5; K-e = 2.8 nM), and nondetectable mu activity with guinea pig ileum (GPI). (ii) N,N-Me-2-Dmt-Tic-OH (12) was equally efficacious in delta receptor binding (K-i(delta) = 0.12 nM; K-i(mu)/K-i(delta) = 20 000), but delta antagonism rose considerably (pA(2) = 9.4; K-e = 0.28 nM) with weak mu antagonism (pA(2) = 5.8; K-e = 1.58 mu M; GPI/MVD = 1:5640). N-Me-(9) and N,N-Me-2-Dmt-Tic-Ala-OH (15) also augmented delta opioid receptor binding, such that 15 demonstrated high affinity (K-i(delta) = 0.0755 nM) and selectivity (K-i(mu)/K-i(delta) = 20 132) with exceptional antagonist activity on MVD (pA(2) = 9.6; K-e = 0.22 nM) and weak antagonism on GPI (pA(2) = 5.8; K-e = 1.58 mu M; GPI/MVD = 1:7180). Although the amidated dimethylated dipeptide analogue 14 had high K-i(delta) (0.31 nM) and excellent antagonist activity (pA(2) = 9.9; K-e = 0.12 nM), the increased activity toward mu receptors in the absence of a free acid function at the C-terminus revealed modest delta selectivity (K-i(mu)/K-i(delta) = 1 655) and somewhat comparable bioactivity (GPI/MVD = 4500). Thus, the data demonstrate that N,N-(Me)(2)-Dmt-Tic-OH (12) and N,N-Me-2-Dmt-Tic-Ala-OH (15) retained high delta receptor affinities and delta selectivities and acquired enhanced potency in pharmacological bioassays on MVD greater than that of other peptide or non-peptide delta antagonists.

  DOI：

  10.1021/jm9607663
• 作为产物：
  描述：

  [4-(氯甲基)-3,5-二甲基苯基]碳酸乙酯 在 sodium hydroxide 、 乙醇 、 sodium ethanolate 作用下， 以 xylene 为溶剂， 反应 8.17h， 生成 4-羟基-alpha,2,6-三甲基-苯丙酸
  参考文献：
  名称：

  Evolution of the Dmt-Tic Pharmacophore:  N-Terminal Methylated Derivatives with Extraordinary δ Opioid Antagonist Activity

  摘要：

  The delta opioid antagonist H-Dmt-Tic-OH (2',6'-dimethyl-L-tyrosyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) exhibits extraordinary delta receptor binding characteristics [K-i(delta) = 0.022 nM; K-i(u)/K-i(delta) = 150 000] and delta antagonism (pA(2) = 8.2; K-e = 5.7 nM). A change in chirality of Dmt at C alpha (1, 2, 6, 8, 10, 13) curtailed delta receptor parameters, while replacement of its alpha-amino function by a methyl group (3) led to inactivity; Tyr-Tic analogues 4 and 11 weakly interacted with delta receptors. N-Alkylation of H-Dmt-Tic-OH and H-Dmt-Tic-Ala-OH with methyl groups produced potent delta-opioid ligands with high delta receptor binding capabilities and enhanced delta antagonism: (i) N-Me-Dmt-Tic-OH 5 had high delta opioid binding (K-i(delta) = 0.2 nM), elevated delta antagonism on mouse vas deferens (MVD) (pA(2) = 8.5; K-e = 2.8 nM), and nondetectable mu activity with guinea pig ileum (GPI). (ii) N,N-Me-2-Dmt-Tic-OH (12) was equally efficacious in delta receptor binding (K-i(delta) = 0.12 nM; K-i(mu)/K-i(delta) = 20 000), but delta antagonism rose considerably (pA(2) = 9.4; K-e = 0.28 nM) with weak mu antagonism (pA(2) = 5.8; K-e = 1.58 mu M; GPI/MVD = 1:5640). N-Me-(9) and N,N-Me-2-Dmt-Tic-Ala-OH (15) also augmented delta opioid receptor binding, such that 15 demonstrated high affinity (K-i(delta) = 0.0755 nM) and selectivity (K-i(mu)/K-i(delta) = 20 132) with exceptional antagonist activity on MVD (pA(2) = 9.6; K-e = 0.22 nM) and weak antagonism on GPI (pA(2) = 5.8; K-e = 1.58 mu M; GPI/MVD = 1:7180). Although the amidated dimethylated dipeptide analogue 14 had high K-i(delta) (0.31 nM) and excellent antagonist activity (pA(2) = 9.9; K-e = 0.12 nM), the increased activity toward mu receptors in the absence of a free acid function at the C-terminus revealed modest delta selectivity (K-i(mu)/K-i(delta) = 1 655) and somewhat comparable bioactivity (GPI/MVD = 4500). Thus, the data demonstrate that N,N-(Me)(2)-Dmt-Tic-OH (12) and N,N-Me-2-Dmt-Tic-Ala-OH (15) retained high delta receptor affinities and delta selectivities and acquired enhanced potency in pharmacological bioassays on MVD greater than that of other peptide or non-peptide delta antagonists.

  DOI：

  10.1021/jm9607663

文献信息

• US7439258B2
  申请人：——

  公开号：US7439258B2

  公开（公告）日：2008-10-21
• [EN] β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF<br/>[FR] EFFECTEURS DE LA BÊTA-ARRESTINE ET COMPOSITIONS ET METHODS D'UTILISATION DE CEUX-CI
  申请人：TREVENA INC

  公开号：WO2021216529A1

  公开（公告）日：2021-10-28

  This application describes a family of compounds acting as β-arrestin effectors that can be used, for example, for treating acute respiratory distress syndrome, for preventing and treating thrombosis, platelet adhesion, and platelet aggregation, and/or for reducing a D-Dimer response, in a subject with ARDS or a viral infection, such as a coronavirus infection.